COMPARE · Reviewed August 3, 2026
DLB vs EFX
Verdict: Side-by-side breakdown using the Bull Rankings model. DLB scored 70.8, EFX scored 70.2 — DLB leads.
Compare another set
DLB
Dolby Laboratories, Inc.
70.8
$60.98 · $5.7B
fundamentals as of
Score gap
0.6
DLB leads
EFX
Equifax Inc.
70.2
$175.51 · $20.6B
fundamentals as of
The model, pillar by pillar (0–100 each)
DLB
stronger →← stronger
EFX
74
Qualityreturns · margins · balance sheet
71
65
Growthrevenue & earnings expansion
81
74
Valuevaluation vs sector peers
60
DLB is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
DLB
EFX
$345mC
FCF
$1.1bC+
+5.9%C+
Rev
+10.3%B
0.02A
D/E
1.21C
25.9xB
P/E
30.8xB
1.29B
PEG
1.72C+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
DLB
EFX
12% below
Price vs fair valuelower is cheaper
12% above
~2%/yr
Growth the price implies10-yr FCF · lower = less priced in
~14%/yr
+9%
1-yr DCF upside
-26%
+14%
5-yr DCF upside
-11%
+21%
10-yr DCF upside
+17%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
DLB
Why this score
- Raising its dividend
EFX
Why this score
- Buying back stock
- Raising its dividend
The companies
DLBDolby Laboratories, Inc.
Why now
Specialty Business Services · market cap $5.7b. 19% off the 52-week high of $75.66. 3 sell-side analysts rate this a Buy with a mean 1-yr target of $78.33 (implying +28% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. FCF converts 152% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
EFXEquifax Inc.
Why now
Consulting Services · market cap $20.6b. Down 35% from 52-week high of $271.84 — deep drawdown territory. Revenue growing +10%, comfortably above the S&P median. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $210.52 (implying +20% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 160% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 35% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 31x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.